The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant interest within the UK , prompting a notable shift in hormone trends. Obtaining these medications remains a complex landscape, with public healthcare system provision currently limited and private clinics offering therapy at a higher cost . Concer